Insights

Strategic Focus BlueRock Therapeutics is actively concentrating on advanced-stage cell therapy programs for neurological and ocular diseases, presenting opportunities to offer specialized manufacturing, clinical trial support, and regulatory navigation services tailored to their pipeline.

Recent Restructuring Following a recent headcount reduction and lab closures, there is potential to provide cost-effective solutions for process automation, laboratory downsizing, and integration of modular bioprocessing platforms to optimize their remaining R&D activities.

Collaborative Alliances BlueRock has established strategic collaborations with Fujifilm and Opsis for developing off-the-shelf iPSC therapies, indicating opportunities to support their ongoing R&D efforts with supply chain management, quality control, and scale-up manufacturing services.

Regulatory Milestones With the FDA granting RMAT designation for their Parkinson’s therapy, BlueRock may require specialized regulatory consulting, manufacturing compliance, and clinical trial logistics to navigate approvals and expand their pipeline.

Market Position As a mid-sized company competing with firms like CRISPR Therapeutics and Beam Therapeutics, BlueRock's focus on cell therapy innovations provides opportunities to offer cutting-edge bioprocessing equipment, automation solutions, and customized cell culture technologies to strengthen their development capabilities.

BlueRock Therapeutics Tech Stack

BlueRock Therapeutics uses 8 technology products and services including Facebook Pixel, Amazon S3, MasterControl, and more. Explore BlueRock Therapeutics's tech stack below.

  • Facebook Pixel
    Analytics
  • Amazon S3
    Content Delivery Network
  • MasterControl
    Document Management Systems
  • Veeva Vault
    Enterprise Content Management
  • ADP HRMS
    Human Resource Management System
  • Google Cloud
    Infrastructure As A Service
  • JSON-LD
    Javascript Frameworks
  • SAP Concur
    Travel And Expense Management

Media & News

BlueRock Therapeutics's Email Address Formats

BlueRock Therapeutics uses at least 1 format(s):
BlueRock Therapeutics Email FormatsExamplePercentage
FLast@bluerocktx.comJDoe@bluerocktx.com
83%
LastF@bluerocktx.comDoeJ@bluerocktx.com
15%
FL@bluerocktx.comJD@bluerocktx.com
2%

Frequently Asked Questions

Where is BlueRock Therapeutics's headquarters located?

Minus sign iconPlus sign icon
BlueRock Therapeutics's main headquarters is located at 238 Main St, Cambridge, Massachusetts 02142, US. The company has employees across 5 continents, including North AmericaEuropeAsia.

What is BlueRock Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
BlueRock Therapeutics's official website is bluerocktx.com and has social profiles on LinkedInCrunchbase.

What is BlueRock Therapeutics's SIC code NAICS code?

Minus sign iconPlus sign icon
BlueRock Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does BlueRock Therapeutics have currently?

Minus sign iconPlus sign icon
As of October 2025, BlueRock Therapeutics has approximately 456 employees across 5 continents, including North AmericaEuropeAsia. Key team members include Chief Technology Officer: C. B.Chief People Officer: R. K. M.Chief Scientific Officer: S. I.. Explore BlueRock Therapeutics's employee directory with LeadIQ.

What industry does BlueRock Therapeutics belong to?

Minus sign iconPlus sign icon
BlueRock Therapeutics operates in the Biotechnology Research industry.

What technology does BlueRock Therapeutics use?

Minus sign iconPlus sign icon
BlueRock Therapeutics's tech stack includes Facebook PixelAmazon S3MasterControlVeeva VaultADP HRMSGoogle CloudJSON-LDSAP Concur.

What is BlueRock Therapeutics's email format?

Minus sign iconPlus sign icon
BlueRock Therapeutics's email format typically follows the pattern of FLast@bluerocktx.com. Find more BlueRock Therapeutics email formats with LeadIQ.

How much funding has BlueRock Therapeutics raised to date?

Minus sign iconPlus sign icon
As of October 2025, BlueRock Therapeutics has raised $225M in funding. The last funding round occurred on Dec 12, 2016 for $225M.

When was BlueRock Therapeutics founded?

Minus sign iconPlus sign icon
BlueRock Therapeutics was founded in 2016.
BlueRock Therapeutics

BlueRock Therapeutics

Biotechnology ResearchUnited States201-500 Employees

BlueRock Therapeutics is a clinical stage cell therapy company focused on creating cellular medicines to treat devastating diseases. We are harnessing the power of cell therapy to create a pipeline of new medicines for people suffering from neurological and ophthalmic diseases. Two of our novel investigational cell therapies, one for the treatment of Parkinson’s disease and one for the treatment of primary photoreceptor diseases, are clinical stage programs. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer, the impact investing arm of Bayer AG that invests in paradigm-shifting breakthrough innovation. In late 2019, BlueRock became a wholly owned, independently operated subsidiary of Bayer AG. Our culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves. For more information, visit www.bluerocktx.com.

Section iconCompany Overview

Headquarters
238 Main St, Cambridge, Massachusetts 02142, US
SIC Code
8733 - Noncommercial Research Organizations
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
201-500

Section iconFunding & Financials

  • $225M

    BlueRock Therapeutics has raised a total of $225M of funding over 1 rounds. Their latest funding round was raised on Dec 12, 2016 in the amount of $225M.

  • $100M$250M

    BlueRock Therapeutics's revenue is estimated to be in the range of $100M$250M

Section iconFunding & Financials

  • $225M

    BlueRock Therapeutics has raised a total of $225M of funding over 1 rounds. Their latest funding round was raised on Dec 12, 2016 in the amount of $225M.

  • $100M$250M

    BlueRock Therapeutics's revenue is estimated to be in the range of $100M$250M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.